C/EBPδ is also induced in human prostate cancer derived cells (LnCAP) and in KCL22 and K562 chronic myelogenous leukemia (CML) cell lines in response to growth arrest and IL-6 family treatments [9,10]. This evidence concerns the gene CEBPD and prostate carcinoma.